ID: ALA2035632

Max Phase: Preclinical

Molecular Formula: C14H12BrN3O2

Molecular Weight: 334.17

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1[nH]c(CN2CCC2)nc2c1oc1ccc(Br)cc12

Standard InChI:  InChI=1S/C14H12BrN3O2/c15-8-2-3-10-9(6-8)12-13(20-10)14(19)17-11(16-12)7-18-4-1-5-18/h2-3,6H,1,4-5,7H2,(H,16,17,19)

Standard InChI Key:  KZLQFLHBCDGIBH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 334.17

Molecular Weight (Monoisotopic): 333.0113

AlogP: 2.64

#Rotatable Bonds: 2

Polar Surface Area: 62.13

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.36

CX Basic pKa: 5.69

CX LogP: 1.40

CX LogD: 1.35

Aromatic Rings: 3

Heavy Atoms: 20

QED Weighted: 0.78

Np Likeness Score: -1.33

References

1. Tsuhako AL, Brown DS, Koltun ES, Aay N, Arcalas A, Chan V, Du H, Engst S, Franzini M, Galan A, Huang P, Johnston S, Kane B, Kim MH, Laird AD, Lin R, Mock L, Ngan I, Pack M, Stott G, Stout TJ, Yu P, Zaharia C, Zhang W, Zhou P, Nuss JM, Kearney PC, Xu W..  (2012)  The design, synthesis, and biological evaluation of PIM kinase inhibitors.,  22  (11): [PMID:22542012] [10.1016/j.bmcl.2012.04.025]

2. Swellmeen L, Shahin R, Al-Hiari Y, Alamiri A, Hasan A, Shaheen O..  (2017)  Structure based drug design of Pim-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors.,  25  (17): [PMID:28760531] [10.1016/j.bmc.2017.07.036]

Source

Source(1):

• Scientific Literature